EPISODE · Jan 26, 2026 · 2 MIN
ACT Brief: De-Identified Data Expands Trial Design, Global Production Normalizes, and FDA Updates Quality Framework
from Applied Clinical Trials · host Applied Clinical Trials
In today’s ACT Brief, we examine how large de-identified datasets are reshaping trial design and site strategy, why global pharmaceutical production is expected to cool after a tariff-driven surge, and what FDA’s new M4Q(R2) draft guidance means for quality submissions.
Embed this episode
Ready to play
ACT Brief: De-Identified Data Expands Trial Design, Global Production Normalizes, and FDA Updates Quality Framework
0:00
2:00
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Applied Clinical Trials?
This episode is 2 minutes long.
When was this Applied Clinical Trials episode published?
This episode was published on January 26, 2026.
Can I download this Applied Clinical Trials episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!